Dicarbonyl electrophile adduct formation

Dicarbonyl electrophile adduct formation refers to a **chemical process** rather than a discrete molecular target. In this process, reactive α-dicarbonyl compounds—such as glyoxal and methylglyoxal—act as **electrophiles** that react irreversibly with nucleophilic amino acid side chains (notably lysine, arginine, and cysteine residues) on proteins. This nonenzymatic post-translational modification leads to the generation of advanced glycation end-products (AGEs), which accumulate over time and are implicated in the pathogenesis of diabetes complications, aging-related diseases, inflammation, and neurodegeneration[2][4]. The reaction is covalent and often irreversible; it alters protein structure/function and can disrupt cellular homeostasis. While "dicarbonyl electrophile adduct formation" describes an important biochemical mechanism—and is a focus for therapeutic intervention via scavenger molecules—it is not itself a canonical drug target like an enzyme or receptor. Instead, it represents a class of chemical modifications that occur under pathological conditions. Drugs such as 2-hydroxybenzylamine act by scavenging these reactive dicarbonyl species before they form harmful adducts[4]. Because this entry describes a **process**, not a single molecule or receptor entity suitable for structured pharmacological targeting nomenclature—and because it lacks standard abbreviations or aliases—it should be flagged as incorrect if used where only canonical targets are appropriate. "α-Dicarbonyl compounds are special types of electrophiles that can react irreversibly with lysine, arginine and cysteine residues via complex mechanisms to form post-translational modifications known as advanced glycation end-products (AGEs). Glyoxal, methylglyoxal...are major endogenous dicarbonyls..."[2]

Covalent adduct formation with nucleophilic amino acid residues (lysine, arginine, cysteine) by dicarbonyl electrophiles [2][4]